Prognostic value of plasma D-dimer levels in lung carcinoma.
AIMS AND BACKGROUNDS: Plasma concentrations of several proteases of the coagulation system have been shown to predict prognosis in malignancy. The study was aimed to investigate the prognostic value of plasma D-dimer concentrations and some other coagulation factors in lung cancer.


METHODS
Between 2004 and 2008, 100 newly diagnosed lung cancer patients and 25 healthy individuals serving as the control group were evaluated. The patients had no history of coagulation system disorders or anticoagulant therapy. Plasma D-dimer concentrations, prothrombin time, activated partial thromboplastin time, international normalized ratio and blood counts of the patients were obtained. Patient age, lung cancer stage, tumor histology, therapy modalities (surgery, chemotherapy and radiotherapy), therapy outcomes and survival durations of the patients were determined.


RESULTS
The median age of the patients (86 males/14 females) was 67 years, and 15% had stage 2, 26% had stage 3A, 24% had stage 3B, and 35% had stage 4 disease. Histologic subtypes were non-small cell carcinoma (87%) and small cell carcinoma (13%). The median D-dimer level of the patients was 1250 ng/dl, which was significantly higher than that of the control group. Survival duration was significantly higher in patients with low D-dimer levels (P <0.05). D-dimer plasma levels predicted survival independently of the clinical stage of disease, histologic tumor type and performance status of the patient (HR = 5.1; 95% confidence interval, 1.015-1.19, P = 0.013). Plasma D-dimer level was significantly higher in metastatic disease (P <0.01).


CONCLUSIONS
The results suggest that D-dimer plasma levels might be useful to predict the clinical outcome and survival of patients with lung cancer.
Department of Chest Diseases, Izmir Dr Suat Seren Chest Diseases and Thoracic Surgery Research and Training Hospital, Izmir, Turkey. bernaeren@hotmail.com
Berna
B
Komurcuoglu
Sadik
S
Ulusoy
Mine
M
Gayaf
Arzu
A
Guler
Emel
E
Ozden
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood*; D001780:Blood Coagulation Tests; D002277:Carcinoma / Q000097:blood* / Q000401:mortality / Q000556:secondary / Q000628:therapy; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood; D018288:Carcinoma, Small Cell / Q000097:blood; D017024:Chemotherapy, Adjuvant; D018450:Disease Progression; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism*; D006801:Humans; D019934:International Normalized Ratio; D008175:Lung Neoplasms / Q000097:blood* / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010314:Partial Thromboplastin Time; D010976:Platelet Count; D011237:Predictive Value of Tests; D011379:Prognosis; D011517:Prothrombin Time; D018714:Radiotherapy, Adjuvant
D014408:Biomarkers, Tumor; D005338:Fibrin Fibrinogen Degradation Products; C036309:fibrin fragment D